Is placental antibody transfer after COVID-19 vaccination different from that after SARS-CoV-2 infection in pregnant individuals? JAMANetwork ChildrensPhila UMich COVID19 coronavirus covid pregnancy vaccination vaccine infection antibody
By Neha MathurNov 11 2022Reviewed by Danielle Ellis, B.Sc. In a recent study published in the JAMA Network Open, researchers investigated the placental transfer ratios of anti-severe acute respiratory syndrome coronavirus 2 antibodies in pregnant females. They did so in two cohorts of pregnant females; the first cohort had females who suffered from natural SARS-CoV-2 infection, and the other had received coronavirus disease 2019 vaccination.
About the study In the present study, researchers used a large group of maternal and cord blood serum samples tested for anti-SARS-CoV-2 antibodies. They assessed the association of time since vaccination, vaccine type, gestational age at delivery, and pregnancy-related complications with the placental transfer of anti-SARS-CoV-2 antibodies.
Study findings Lab Diagnostics & Automation eBook Compilation of the top interviews, articles, and news in the last year. Download a copy today The authors noted that the concentration of IgG antibodies to SARS-CoV-2 S was present in higher concentrations after messenger ribonucleic acid vaccination compared with the antibodies elicited by symptomatic or asymptomatic COVID-19.
Furthermore, the authors found no difference in maternal IgG level or transfer ratios for preterm and term deliveries when accounting for the time since vaccination to delivery. Fewer females had a documented SARS-CoV-2 infection before the current pregnancy, but transfer ratios were still robust. Although the present study did not address the effectiveness of COVID-19 vaccination in preventing infection among pregnant females or newborns, they found that antibody levels after vaccination with an mRNA vaccine were at least 10-fold higher than the levels after infection. Furthermore, the mRNA-1273 vaccine elicited higher antibody levels than the BNT162b2 vaccine.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
The spectrum of SARS-CoV-2–related neurologic involvement among children and adolescents in 2021The spectrum of SARS-CoV-2–related neurologic involvement among children and adolescents in 2021 JAMANetwork BostonChildrens HopkinsMedicine IowaMed SARSCoV2 COVID19 coronavirus covid neuroscience neurology
Weiterlesen »
Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke RegistryBackground and objectives: COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19. Methods: Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). Results: Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16–2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20–2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23–1.99), 24-hour (OR 2.47; 95% CI 1.58–3.86) and 3-month mortality (OR 1.88; 95% CI 1.52–2.33). COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26–1.60). Discussion: Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgro
Weiterlesen »
The comparative risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273 second dosesThe comparative risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273 second doses UBC UofT vaccine vaccination myocarditis mRNA mRNAvaccine
Weiterlesen »
How long COVID is defined and measured affects prevalence estimationIn a recent study posted to the medRxiv* preprint server, researchers evaluated the prevalence of long coronavirus disease (COVID) symptoms, functional disabilities, symptoms, and pathological alterations among adults and children ≥12 weeks post-acute COVID 2019 (COVID-19).
Weiterlesen »